MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1161/circulationaha.112.128132

Медицинская библиотека · Circulation · 2013

Prospective, multicenter study of ventricular assist device infections.

Gordon Rachel J, Weinberg Alan D, Pagani Francis D, Slaughter Mark S, Pappas Pat S, Naka Yoshifumi, Goldstein Daniel J, Dembitsky Walter P, Giacalone Julie C, Ferrante Jennifer, Ascheim Deborah D, Moskowitz Alan J, Rose Eric A, Gelijns Annetine C, Lowy Franklin D, Ventricular Assist Device Infection Study Group

Клиническое исследованиеСтатьяМногоцентровое исследованиеПоддержка NIH: внешняя программаПеревод пока не подготовлен

Аннотация

BACKGROUND

Ventricular assist devices (VADs) improve survival and quality of life in patients with advanced heart failure, but their use is frequently complicated by infection. There are limited data on the microbiology and epidemiology of these infections.

METHODS AND

RESULTS

One hundred fifty patients scheduled for VAD implantation were enrolled (2006-2008) at 11 US cardiac centers and followed prospectively until transplantation, explantation for recovery, death, or for 1 year. Eighty-six patients (57%) received HeartMate II devices. Data were collected on potential preoperative, intraoperative, and postoperative risk factors for infection. Clinical, laboratory, and microbiological data were collected for suspected infections and evaluated by an infectious diseases specialist. Thirty-three patients (22%) developed 34 VAD-related infections with an incidence rate of 0.10 per 100 person-days (95% confidence interval, 0.073-0.142). The median time to infection was 68 days. The driveline was the most commonly infected site (n=28); 18 (64%) were associated with invasive disease. Staphylococci were the most common pathogen (47%), but pseudomonas or other Gram-negative bacteria caused 32% of infections. A history of depression and elevated baseline serum creatinine were independent predictors of VAD infection (adjusted hazard ratio=2.8 [P=0.007] and 1.7 [P=0.023], respectively). The HeartMate II was not associated with a decreased risk of infection. VAD infection increased 1-year mortality (adjusted hazard ratio=5.6; P<0.0001).

CONCLUSIONS

This prospective, multicenter study demonstrates that infection frequently complicates VAD placement and is a continuing problem despite the use of newer, smaller devices. Depression and renal dysfunction may increase the risk of VAD infection. VAD infection is a serious consequence because it adversely affects patient survival.

CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01471795.

Для цитирования: Gordon Rachel J, Weinberg Alan D, Pagani Francis D, Slaughter Mark S, Pappas Pat S, Naka Yoshifumi, Goldstein Daniel J, Dembitsky Walter P, Giacalone Julie C, Ferrante Jennifer, Ascheim Deborah D, Moskowitz Alan J, Rose Eric A, Gelijns Annetine C, Lowy Franklin D, Ventricular Assist Device Infection Study Group. Prospective, multicenter study of ventricular assist device infections.. Circulation. 2013. DOI: 10.1161/circulationaha.112.128132.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.